Infectious cell culture supernatant containing Dengue virus type 1 strain DENV-1/CaGa/INMI/COD/2019. This strain is preserved under Viral Storage Medium -80C and is Mycoplasma free.
Lyophilized ready-to-use primers and probe (Lyoph-P&P, 96 rxns in the form of 24x4 rxns) for real time RT-PCR of Tick borne encephalitis virus (Taqman)
SOPs in the attached pdf.
Disclaimer: This product does not contain the polymerase.
For RUO (research use only).
The lyophilized, non infectious, encapsidated RNA (Armored RNA) contains the sequence of the NS3 and 3'UTR region from Tick borne encephalitis virus and can be used as positive control for extraction and real time RT-PCR.
Extraction is mandatory before use in real time RT-PCR.
Packaged for 100 Rxns, for RUO (Research Use Only).
SOPs in the attached pdf.
SARS-CoV-2 isolated from a human oro-nasal combined swab. Omicron BA.2, Pango Lineage B.1.1.529.2.9. Passage 3 grown in hSLAM cells. Sequencing performed after purchase.
SARS-CoV-2 isolated from a human oro-nasal combined swab. Omicron BA.2, pango lineage B.1.1.529.2. Passage 3 grown in hSLAM cells. Sequencing performed after purchase.
SARS-CoV-2 isolated from a human oro-nasal combined swab. Omicron BA.2, Pango Lineage B.1.1.529. Passage 3 grown in hSLAM cells. Sequencing performed after purchase.
Plasmid contains the entire genome of HIV-1 with specific mutations in the reverse transcriptase gene, which can confer drug resistance to specific HIV-1 inhibitors. The respective mutations have been reported in viruses from HIV-infected individuals on reverse transcriptase inhibitors with virologic therapy failure.
Plasmid contains the entire genome of HIV-1 with a specific mutation in the protease gene, which has been described as a polymorphic mutation. It is unclear, whether it can confer drug resistance to specific HIV-1 PR inhibitors directly. It has been shown in cell culture that the presence of the 63P change leads to higher "replicative fitness" of the virus. The respective mutations have been reported in viruses from HIV-infected individuals on PR inhibitors with virologic therapy failure.
Plasmid contains the entire genome of HIV-1 with specific mutations in the protease gene, which can confer drug resistance to specific HIV-1 PR inhibitors. The respective mutations have been reported in viruses from HIV-infected individuals on PR inhibitors with virologic therapy failure.
Plasmid contains the entire genome of HIV-1 with specific mutations in the protease gene, which can confer drug resistance to specific HIV-1 PR inhibitors. The respective mutations have been reported in viruses from HIV-infected individuals on PR inhibitors with virologic therapy failure.
Plasmid contains the entire genome of HIV-1 with specific mutations in the protease gene, which can confer drug resistance to specific HIV-1 PR inhibitors. The respective mutations have been reported in viruses from HIV-infected individuals on PR inhibitors with virologic therapy failure.
Plasmid contains the entire genome of HIV-1 with specific mutations in the protease gene, which can confer drug resistance to specific HIV-1 PR inhibitors. The respective mutations have been reported in viruses from HIV-infected individuals on PR inhibitors with virologic therapy failure.
Plasmid contains the entire genome of HIV-1 with specific mutations in the protease gene, which can confer drug resistance to specific HIV-1 PR inhibitors. The respective mutations have been reported in viruses from HIV-infected individuals on PR inhibitors with virologic therapy failure.